Microbial metabolites in chemotherapy-induced cognitive impairment: from mechanistic associations to pharmacological target validation
Abstract
Chemotherapy-induced cognitive impairment (CICI) encompasses heterogeneous changes in memory, attention, executive function and processing speed. Microbial metabolites offer experimentally tractable candidates because their exposure, dose–response relationships and host-target engagement can be measured. This review evaluates short-chain fatty acids (SCFAs), microbial indoles and host kynurenine metabolism, and microbially modified bile acids, while considering microbial inflammatory products as distinct modifiers of the intestinal–brain environment. Evidence is assessed against five criteria: CICI specificity, temporal sequence, selective causal manipulation, host-target engagement and oncological compatibility. Clinical microbiome associations and probiotic intervention findings support further investigation, but do not establish mediation by an individual metabolite. Selected chemotherapy models provide cognitive and molecular intervention evidence, although its strength varies by agent, metabolic pathway and behavioral endpoint. Changes in metabolite concentrations may reflect altered diet, epithelial absorption, host metabolism or clearance as well as microbial production. Translation therefore requires regimen-specific longitudinal sampling, compartment- appropriate exposure measurements, selective pathway perturbation and domain-specific cognitive assessment with controls for sickness and motor impairment. Cognitive protection must also be evaluated alongside chemotherapy exposure, tumor control and infectious safety. This framework distinguishes biomarkers of treatment-associated injury from causal mediators and identifies the evidence needed to develop metabolite-guided pharmacological interventions.
Related
- Comparative efficacy of non-pharmacological interventions for amnestic mild cognitive impairment: a network meta-analysis
- Pigeonpea leaves in orthopedic diseases: bioactive metabolites, pharmacological actions and therapeutic potential
- Pharmacological regulation of chondrocyte ferroptosis by plant-derived metabolites in osteoarthritis: from molecular mechanisms to targeted nanodelivery
- Mechanistic insights into the potential role of botanical drugs and plant-derived metabolites in mitigating oxidative stress in varicocele
- Pharmacological targeting of bunyavirus-induced synaptic impairment prevents neuronal hyperexcitability
BibTeX
@article{tian2026microbial,
title = {{Microbial metabolites in chemotherapy-induced cognitive impairment: from mechanistic associations to pharmacological target validation}},
author = {Yuanyuan Tian and Wentao Li and Juyue Zhou and Jianchun Yu},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1968616},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1968616},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Microbial metabolites in chemotherapy-induced cognitive impairment: from mechanistic associations to pharmacological target validation
AU - Yuanyuan Tian
AU - Wentao Li
AU - Juyue Zhou
AU - Jianchun Yu
PY - 2026
DA - 2026/10/30
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1968616
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1968616
AB - Chemotherapy-induced cognitive impairment (CICI) encompasses heterogeneous changes in memory, attention, executive function and processing speed. Microbial metabolites offer experimentally tractable candidates because their exposure, dose–response relationships and host-target engagement can be measured. This review evaluates short-chain fatty acids (SCFAs), microbial indoles and host kynurenine metabolism, and microbially modified bile acids, while considering microbial inflammatory products as distinct modifiers of the intestinal–brain environment. Evidence is assessed against five criteria: CICI specificity, temporal sequence, selective causal manipulation, host-target engagement and oncological compatibility. Clinical microbiome associations and probiotic intervention findings support further investigation, but do not establish mediation by an individual metabolite. Selected chemotherapy models provide cognitive and molecular intervention evidence, although its strength varies by agent, metabolic pathway and behavioral endpoint. Changes in metabolite concentrations may reflect altered diet, epithelial absorption, host metabolism or clearance as well as microbial production. Translation therefore requires regimen-specific longitudinal sampling, compartment- appropriate exposure measurements, selective pathway perturbation and domain-specific cognitive assessment with controls for sickness and motor impairment. Cognitive protection must also be evaluated alongside chemotherapy exposure, tumor control and infectious safety. This framework distinguishes biomarkers of treatment-associated injury from causal mediators and identifies the evidence needed to develop metabolite-guided pharmacological interventions.
SN - 1663-9812
ER -